| ALKERMES PLC DL-,01 |
| Irland |
| Gesundheit |
| IE00B56GVS15 / A1JKVH |
| 8AK (Frankfurt) / ALKS (NASDAQ) |
| FRA:8AK, ETR:8AK, 8AK:GR, NASDAQ:ALKS |
| - |
| https://www.alkermes.com/ |
|
Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bip..
>Volltext.. |
| 6337.91 Mio. EUR |
| 7139.36 Mio. EUR |
| 1451.99 Mio. EUR |
| 178.75 Mio. EUR |
| 57.57 Mio. EUR |
| 0.35 EUR |
| 1369.2 Mio. EUR |
| 445.38 Mio. EUR |
| 218.7 Mio. EUR |
| 0.99 |
| 14.27% |
| -80.43% |
| - |
| - |
| - |
| ALKERMES |
| 21.09.26 |
|
||||
|